Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI

Document Type

Article

Publication Date

10-1-2018

Publication Title

Journal of thrombosis and thrombolysis

Keywords

Anticoagulants, Atrial Fibrillation, Female, Humans, Male, Michigan, Patient Selection, Quality Improvement, Randomized Controlled Trials as Topic, Registries, Thromboembolism, Treatment Outcome, Warfarin

Abstract

Randomized controlled trials (RCTs) examining warfarin use for stroke prevention in atrial fibrillation (AF) may not accurately reflect real-world populations. We aimed to determine the representativeness of the RCT populations to real-world patients and to describe differences in the characteristics of trial populations from trial eligible patients in a real-world setting. We hypothesized that a significant fraction of real-world patients would not qualify for the RE-LY, ROCKET-AF, and ARISTOTLE trials and that real-world patients qualifying for the studies may have more strokes and bleeding events. We compared the inclusion and exclusion criteria, patient characteristics, and clinical outcomes from RE-LY, ROCKET-AF, and ARISTOTLE against data from the Michigan Anticoagulation Quality Improvement Initiative (MAQI

Medical Subject Headings

Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Michigan; Patient Selection; Quality Improvement; Randomized Controlled Trials as Topic; Registries; Thromboembolism; Treatment Outcome; Warfarin

PubMed ID

29948756

Volume

46

Issue

3

First Page

316

Last Page

324

Find It @ Sladen

Share

COinS